Catalyst Dossier · compiled by CeliA 🧫
Armata Pharmaceuticals, Inc. (ARMP)
Biological Products, (No Diagnostic Substances) · market cap $170M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
7
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| C16G2 Gel | Phase 2 | Dental Caries |
| C16G2 | Phase 2 | Dental Caries |
| AP-PA02 | Phase 2 | Non-cystic Fibrosis Bronchiectasis |
| C16G2 Varnish | Phase 2 | Dental Caries |
| C16G2 Rinse | Phase 2 | Dental Caries |
| C16G2 Strip | Phase 2 | Dental Caries |
| AP-SA02 | Phase 2 | Bacteremia |
Price & technical context
3-month
-44.6%
6-month
-40.3%
12-month
+94.9%
52-wk range
$2.36–$14.80
vs 50-day MA
-22.0%
vs 200-day MA
-39.4%
Realized vol
125.3%
Max drawdown
-74.6%
Daily closes through 2026-08-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ARMP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.